NCT00535314撤回2 期
A Multicenter, Phase II, Randomized, Open Label Trial of 2 Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 发起方
- Biogen
- 主要终点
- To determine the proportion of patients without progression at 6 months in patients with unresectable Stage III or Stage IV melanoma treated with RTA 402.
研究概览
简要总结
The primary purpose of the study is to determine the proportion of patients without progression at 6-months in patients with unresectable Stage III or Stage IV melanoma who are taking RTA 402.
详细描述
This is a phase II, open label, randomized study in patients with unresectable Stage III or Stage IV malignant melanoma. Patients will be randomly assigned to two different doses of RTA 402 administered orally once daily for 28 consecutive days, for up to 18 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Greater than or equal to 18 years of age
- •Confirmed diagnosis of malignant (unresectable Stage III or Stage IV) melanoma
- •Measurable disease, defined as at least 1 lesion which measures more than or equal to 20 mm by conventional techniques, or more than or equal to 10 mm by spiral CT scan, or cutaneous lesion of greater than or equal to 10 mm by caliper.
- •May have received no more than 1 prior chemotherapy for metastatic disease.
- •May have received prior vaccine therapy in the adjuvant setting.
- •May have received cytokine therapy in the adjuvant setting and/or 1 prior cytokine therapy for metastatic disease.
- •ECOG performance of 0-1
- •Must have adequate liver and renal function documented by laboratory test results.
- •Must have adequate bone marrow function documented by lab results.
- •Must have completed any prior chemotherapy, immunotherapy, radiation, biological, or other investigational cancer therapy at least 4 weeks prior to starting this study, and have recovered from all acute side effects. Patients receiving mitomycin C or nitrosoureas must be 6 weeks from the last administration of chemotherapy.
- •Man or woman must agree to practice effective contraception during the study and for at least 2 months after the last dose of RTA
- •Must have life expectancy of more than 3 months.
- •Must be willing and able to sign the informed consent form.
- •Must be willing and able to take and document oral doses of RTA 402.
排除标准
- •May have received no more than 1 prior chemotherapy.
- •May have received no more than 1 prior cytokine therapy for metastatic disease.
- •Diagnosis of ocular melanoma.
- •Inability to swallow tablets or capsules
- •Symptomatic malabsorptive disorder (eg, Crohn's Disease), or removal of either the terminal ileus or more than 2/3 of the small intestine.
- •Active brain metastases or primary central nervous system malignancies; patients with a previously treated brain metastasis may be included provided that there is no requirement for steroids and no evidence for progression for greater than or equal to 8 weeks after treatment.
- •Active second malignancy.
- •Weight loss greater than or equal to 10% over the 6 weeks prior to dosing
- •Pregnant or breast feeding
- •Clinically significant illnesses which could compromise participation in the study, including: uncontrolled diabetes; active or uncontrolled infection; acute or chronic liver disease; confirmed diagnosis of HIV infection; uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the last 6 months, or uncontrolled cardiac arrhythmia.
- •Psychiatric illness that would limit compliance with study requirements.
研究组 & 干预措施
RTA 402 Dose1
Experimental
Dose1 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
干预措施: RTA 402 Dose1 (Drug)
RTA 402 Dose2
Experimental
Dose2 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
干预措施: RTA 402 Dose2 (Drug)
结局指标
主要结局
To determine the proportion of patients without progression at 6 months in patients with unresectable Stage III or Stage IV melanoma treated with RTA 402.
次要结局
- To determine the overall response rate and duration of responses
研究者
相似试验
进行中（未招募）
2 期
Study Investigating the Safety and Immunogenicity of AB-729 and VTP 300 in Virologically Suppressed CHB ParticipantsVirologically-Suppressed Chronic Hepatitis BInfection - Other infectious diseasesACTRN12622000317796Arbutus Biopharma62
已完成
2 期
A Phase IIb, open label, sequential cohort study comparing KappaMab alone to KappaMab in combination with lenalidomide and low dose dexamethasone (MRd) in Relapsed Refractory Multiple MyelomaACTRN12616001164482Dr Andrew Spencer - Alfred Hospital59
进行中（未招募）
1 期
A study to compare two different formulations of fenebrutinib and to assess the effect of food and rabeprazole on the processing of fenebrutinib by the body in healthy participantsISRCTN23183841F. Hoffmann-La Roche Ltd84
进行中（未招募）
1 期
A study to investigate the use of the study drug Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab with or without Chemotherapy for solid tumours.Patients with with locally advanced or metastatic solid tumors.MedDRA version: 21.1Level: LLTClassification code 10065143Term: Malignant solid tumourSystem Organ Class: 100000004864EUCTR2019-003474-35-DEektar Therapeutics400
进行中（未招募）
1 期
A study to investigate the use of the study drug NKTR-214 in combination with Pembrolizumab for solid tumoursEUCTR2019-003474-35-ITEKTAR THERAPEUTICS98